Regional differences in hepatitis C treatment with peginterferon and ribavirin in Japan: a retrospective cohort study

about

Regional differences in hepatitis C treatment with peginterferon and ribavirin in Japan: a retrospective cohort study

Item

http://www.wikidata.org/entity/Q36733568

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Regional differences in hepati ...... : a retrospective cohort study

@ast

Regional differences in hepati ...... : a retrospective cohort study

@en

type

Item

label

Regional differences in hepati ...... : a retrospective cohort study

@ast

Regional differences in hepati ...... : a retrospective cohort study

@en

prefLabel

Regional differences in hepati ...... : a retrospective cohort study

@ast

Regional differences in hepati ...... : a retrospective cohort study

@en

P1476

Regional differences in hepati ...... : a retrospective cohort study

@en

P2093

Hiroshi Yamada

http://www.w3.org/2001/XMLSchema#string

Naohiko Masaki

http://www.w3.org/2001/XMLSchema#string

P2860

An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases

Diagnosis, management, and treatment of hepatitis C: an update

Geographic variation in the treatment of acute myocardial infarction: the Cooperative Cardiovascular Project.

Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial.

Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C.

Regional disparities in interferon therapy for chronic hepatitis C in Japan: a nationwide retrospective cohort study.

A framework for management of hepatitis C in prisons.

Analysis of site performance in academic-based and community-based centers in the IDEAL Study.

New hepatitis C therapies: the toolbox, strategies, and challenges.

Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial.

P304

1217-1223

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/DDDT.S102458

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P50

Kazuki Ide

Yohei Kawasaki

P577

2016-03-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27042013

http://www.w3.org/2001/XMLSchema#string

P932

4809336

http://www.w3.org/2001/XMLSchema#string